Boehringer Ingelheim UK is part of a global biopharmaceutical company dedicated to improving health for people and animals. Founded in Germany in 1885, the organisation has grown from a small family business into one of the world’s leading research-driven healthcare groups.
Its work covers prescription medicines, veterinary treatments, clinical research and biopharmaceutical manufacturing. Through science, responsible healthcare and long-term investment, Boehringer Ingelheim UK supports better outcomes for patients, families, animals and communities.
What Is Boehringer Ingelheim UK?
Boehringer Ingelheim UK operates as the United Kingdom branch of the wider Boehringer Ingelheim group. Its main registered office is located on Ellesfield Avenue in Bracknell, Berkshire. The company works across human health and animal health. It also supports medicine supply, medical affairs, regulatory work, clinical research, patient safety and professional partnerships within the UK healthcare system.
Boehringer Ingelheim UK and Ireland are managed as a regional organisation, but they operate through separate legal companies. The UK business includes Boehringer Ingelheim Limited and Boehringer Ingelheim Animal Health UK Limited, while Ireland has its own registered company in Dublin.
Boehringer Ingelheim UK Quick Information
| Category | Details |
|---|---|
| Company | Boehringer Ingelheim UK |
| Industry | Pharmaceuticals and healthcare |
| Main focus | Human health and animal health |
| Founded | 1885 |
| UK headquarters | Bracknell, Berkshire |
| Global headquarters | Ingelheim am Rhein, Germany |
| Global employees | Approximately 54,300 |
| UK operations | Medicines, research, distribution and veterinary health |
| Recent development | AI and machine-learning centre in London |
| Website | www.boehringer-ingelheim.com |
A Company Built on Long-Term Healthcare
Albert Boehringer founded the company in 1885 in Ingelheim am Rhein, Germany. Its early work involved chemical manufacturing, but the organisation gradually moved towards pharmaceutical research and healthcare. A dedicated research department was created in 1917. This early commitment to science shaped the company’s modern identity and helped establish research as one of its most important strengths.
The business remains independent and family-owned. This structure allows it to plan for future generations and invest in new therapies without focusing only on short-term financial results.
Human Health Services and Medical Research
Human health is one of the central areas of Boehringer Ingelheim UK. The company focuses on conditions where patients may still need better, safer or more effective treatment options. Its medical research includes respiratory disease, heart failure, diabetes, chronic kidney disease, pulmonary fibrosis, cancer, immunology and neurological conditions. Many of these diseases affect patients for many years and require continuous medical support.
Well-known medicines connected with the company include JARDIANCE® and OFEV®. JARDIANCE® is associated with diabetes, heart failure and kidney care, while OFEV® is used in the management of certain fibrotic lung diseases. Medicines must always be used under the direction of a qualified doctor or pharmacist. Treatment choices depend on a patient’s condition, medical history, other medicines and professional guidance.
Boehringer Ingelheim UK and Animal Health
Animal health is another major part of the company’s work. Boehringer Ingelheim develops veterinary medicines, vaccines and parasite-control products for pets, horses and farm animals. Its animal-health services support dogs, cats, horses, cattle, pigs and poultry. Healthy animals also support human wellbeing, food safety and the wider environment.
The company provides products for disease prevention, parasite control and treatment. In the UK, pet owners can find veterinary products such as FRONTLINE® through approved channels. Veterinary medicines should be used according to the advice of a veterinary professional. The correct product, dose and treatment period depend on the animal’s species, age, weight and medical needs.
Pharmaceutical Research and New Treatments
Research and development remain at the heart of Boehringer Ingelheim’s work. In 2025, the global group invested €6.4 billion in research and development, representing a significant share of its total sales. The company employs approximately 54,300 people and serves more than 130 markets. Its global research network includes major sites in Germany, the United States, Austria, France, China and Japan.
Recent progress has included new medicines for lung cancer and pulmonary fibrosis. JASCAYD®, also known as nerandomilast, received approval in the United Kingdom in July 2026 for adults with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. The medicine is available only on prescription. Patients should follow approved medical guidance and discuss any side effects with a doctor, pharmacist or nurse.
Artificial Intelligence and Healthcare Innovation
Boehringer Ingelheim is also investing in artificial intelligence and computational biology. In 2026, it launched a new AI Accelerator in King’s Cross, London. The company plans to invest £150 million over ten years in this centre. The facility will bring together specialists in artificial intelligence, machine learning, human genetics and computational biology.
The purpose is to improve the understanding of disease and support the discovery of new treatments. The company expects to build a team of 50 AI experts by the end of 2027. This investment strengthens the UK’s position as a centre for life sciences and medical technology. It may also create new opportunities for scientists, data specialists, researchers and healthcare professionals.
Biopharmaceutical Manufacturing
Boehringer Ingelheim also provides biopharmaceutical contract manufacturing services through its BioXcellence business. This division develops and manufactures biological medicines for other healthcare companies. It uses advanced production methods involving microorganisms and mammalian cell cultures.
Biological medicines can be complex to produce because they are made using living cells or biological systems. Quality control, sterile production and careful temperature management are essential throughout the process. The company’s manufacturing network supports the supply of medicines to patients in many parts of the world.
Safety, Quality and Medical Support
Medicine safety is an important responsibility for Boehringer Ingelheim UK. The company provides channels for suspected side effects and other adverse events to be shared with its safety teams. Patients can also use the UK Yellow Card Scheme to report suspected side effects. Anyone experiencing a serious or worrying reaction should seek urgent medical help.
The company’s Bracknell site holds a wholesale distribution authorisation from the Medicines and Healthcare products Regulatory Agency. This allows the regulated procurement and supply of prescription medicines and products requiring special handling. Medicine approval, product availability and approved uses may differ between countries. Patients should always follow UK prescribing guidance and use official patient leaflets.
Sustainable Development for Generations
Boehringer Ingelheim follows a sustainability programme called “Sustainable Development – For Generations”. This approach connects healthcare, environmental responsibility and social progress. The programme is based on three main areas: More Health, More Green and More Potential.
More Health focuses on better care for people and animals. More Green aims to reduce environmental harm and protect natural resources. More Potential supports employees, communities, partners and social-health initiatives. The company believes that sustainability should be included throughout its operations, from research and manufacturing to supply chains and community work.
Careers at Boehringer Ingelheim UK
Boehringer Ingelheim UK offers career opportunities in medicine, science, manufacturing, regulatory affairs, veterinary health, data science, supply chain and business management. Its vacancies may include permanent and temporary positions. The company welcomes people with different professional backgrounds who want to contribute to human and animal health.
The organisation places strong value on teamwork, openness, respect and equal opportunity. Employees work with colleagues from different countries and professional fields. For students and experienced professionals, the company can offer opportunities to develop skills in one of the world’s most important healthcare industries.
Final Thoughts
Boehringer Ingelheim UK combines medical research, patient care, animal health, regulated medicine supply and modern technology. Its Bracknell operation supports the UK and Ireland, while its global network delivers research and manufacturing capabilities across many countries.
The company’s future direction is shaped by investment in innovative treatments, artificial intelligence, sustainability and clinical research. Its work remains focused on areas where patients and animals need better healthcare solutions.
Through its independent ownership and long-term approach, Boehringer Ingelheim UK continues to play an important role in building healthier communities and improving lives for future generations.
Also Read
